Neovasc Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCN research report →
About the company
Neovasc Inc. is a specialized medical technology enterprise focused on the development, production, and worldwide distribution of products for the cardiac health sector, with a significant presence across Europe and other international markets. The company's key innovations feature the Tiara system, an advanced transcatheter technology for managing mitral valve disease, and the Neovasc Reducer, which offers a therapeutic option for patients suffering from refractory angina.
- CEO
- Fredericus A. Colen
- IPO
- 2001
- Employees
- 49
- HQ
- Richmond, BC, CA
Price Chart
- Market Cap
- $82.86M
- P/E
- -1.99
- P/S
- 21.78
- P/B
- 5.18
- EV/EBITDA
- -1.78
- Div Yield
- 0.00%
- Gross Margin
- 79.66%
- Op Margin
- -886.75%
- Net Margin
- -1082.90%
- ROE
- -121.07%
- ROIC
- -116.83%
- Revenue
- $3.81M · 49.37%
- Net Income
- $-41,204,418 · -65.55%
- EPS
- $-15.07 · -52.53%
- Op Income
- $-33,740,809
- FCF YoY
- 8.41%
- 52W High
- $30.07
- 52W Low
- $4.58
- 50D MA
- $29.31
- 200D MA
- $15.47
- Beta
- 2.01
- Avg Volume
- 25.78K
Get TickerSpark's AI analysis on NVCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NVCN coverage
Recent articles, reports, and earnings notes.
No research on NVCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVCN report →Similar companies
Peers in the same neighborhood.